Abstract:Objective:To evaluate the efficacy of polymyxin B and recombinant human epidermal growth factor on anti-infection and healing of wounds in patients with deep II degree burns. Methods:92 cases of deep second-degree burns admitted during March 2015-October 2016 were selected and divided into 46 cases in the control group and 46 cases in the observation group by randomized grouping method; patients in the control group were treated with recombinant human epidermal growth factor, while patients in the observation group were treated with polymyxin B on the basis of the control group, and the incidence of infection and wound healing of the patients
in the two groups were compared. The incidence of infection and wound healing were compared between the two groups. Results: In the observation group, the incidence of wound infection was lower than that in the control group at 1, 2 and 3 weeks of treatment (P<0.05), the wound healing rate was higher than that in the control group (P<0.05), and the time of granulation tissue growth was earlier than that in the control group (P<0.05); and the differences in the incidence of scarring between the two groups were not statistically significant after comparison between the groups (P>0.05). Conclusion: The use of polymyxin B and recombinant human epidermal growth factor in the treatment of burn patients avoided the occurrence of wound infection and promoted the healing of infected wounds.
SONG Bin-Sheng, HU Wei-Dong, WEN Zhen-Hua. Evaluation of the efficacy of polymyxin and recombinant human epidermal growth factor on anti-infection and healing of wounds in patients with deep second-degree burns[J]. Anti-infective Pharmacology, 2018, 15 (01): 139-141.